Company intelligence / Profile preview
Il-Yang Pharmaceutical
- Ownership
- Private
- Development stage
- Commercial
Overview
Il-Yang Pharmaceutical has developed several first-in-class drugs in Korea including Noltec® (ilaprazole) for acid-related diseases and Supect® (radotinib) for CML. The company also manufactures WHO-prequalified trivalent influenza vaccine and exports to countries with low vaccine availability. It has a robust R&D pipeline focused on small molecules and biologics such as cytokine-based therapies. Clinical results include multinational approvals for key products.
- Therapeutic areas
- GastroenterologyInfectious DiseasesOncologyMen's Health
- Modalities
- Small moleculesinactivated vaccinesprophylactic vaccinesmultivalent vaccinescytokine-based biologics
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Il-Yang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Il-Yang Pharmaceutical.